Member Info for donotpanic

Can not buy on Halifax but can sell

London, UK - 7 June 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its wholly owned subsidiary ProAxsis Limited ("ProAxsis" or the Company") has entered into an exclusive licensing agreement with the global biopharmaceutical company AstraZeneca. ProAxsis will take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA (enzyme-linked immunosorbent assay) developed by an internal research team at AstraZeneca. In return for providing access to the required intellectual property and technical know-how, AstraZeneca will receive a royalty fee on future Global net sales of the assay.

Typical TREE SHAKE

This will be over 2-3 pounds in coming Months... once we get news landing

Not easy to buy now... any one waiting this is cheap with all the news due

are now piling in could be BLUE CLOSE

Could be dividend coming to... this reminds me of BRH...

It is a GIFT at these prices ... BUY -HOLD

Those who bought at 130 will be in Money... remember when ARB raised at 80 then dropped to around 65-70 every one was saying same thing... within few months it went to over 200 ... Those investors are not worried about few pence drop...

https://www.proactiveinvestors.co.uk/companies/news/952401/netscientific-follows-its-money-as-investee-company-announces-plans-to-raise-us45mln-952401.html BUY BUY

Remember this was under a penny at some point.. at some point we could see this over pound...

Lot buyers were shown Red... think this will turn from here and we could have HIT the Bottom today.

I think we still hold same percentage but due to dilution it may look lower

FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced the presentation of interim data from the Phase 2 trial led by the National Cancer Institute (NCI), of the National Institutes of Health (NIH), at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.



The Phase 2 trial (NCT04287868) studies PDS0101 (Versamune®-HPV16) in combination with two investigational immune-modulating agents: bintrafusp alfa (M7824), a bifunctional "trap" fusion protein targeting TGF-ß and PD-L1, and NHS-IL12 (M9241), a tumor-targeting immunocytokine. PDS0101 is an immunotherapy candidate designed to treat cancers caused by infection with HPV16 (HPV16-positive cancers) by activating the immune system to produce in vivo CD8+ (killer) T-cells to target and kill tumors that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing. Money in BANK wait now till we get NEWS starting and BOOM... Remember how quickly this went over 200

The project is due to end in August 2021 and discussions regarding commercialization are ongoing with system manufacturers who are already part of the project team. Could be Chinese? As BRH are in final stages now

We will see how market reacts... there was defo buying pressure into close yesterday and I expect we could break through 50p barrier

Read yesterdays RNS... This is a BUY

We may get HOLDING RNS tomorrow

Dep pockets knows what is coming or TB COULD BE BUYING BACK... ANY ONE SELLING NOW SHOULD WAIT AFTER YEATERDAYS RNS

BRH shares have fallen significantly since late March and are now trading near a support level that could trigger the next rally if it holds over the next few weeks.

However, a positive development from the investment company could be what buyers need to jump in and push prices higher.